Literature DB >> 12460067

Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.

Rosemary L Donne1, Ian Abbs, Peter Barany, Carl-Gustaf Elinder, Mark Little, Peter Conlon, Timothy H J Goodship.   

Abstract

There is a significant risk of disease recurrence in patients with nondiarrheal (D-) hemolytic uremic syndrome (HUS) undergoing renal transplantation. Recent studies have found that approximately 20% of sporadic cases of HUS have mutations in the gene for the complement regulatory protein factor H. The authors report on 2 families, in each of which a family member initially presented with sporadic HUS and subsequently received a live-related renal transplant, one from a sibling and the other from the father. Subsequently, both recipients suffered recurrent HUS in the allograft, and both donors had HUS within a year of the transplant. Neither family has a factor H mutation. This report underlines the risk of disease recurrence in recipients associated with live-related renal transplantation in HUS and also suggests that the donors may be at risk. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12460067     DOI: 10.1053/ajkd.2002.36938

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

Review 1.  Living donor kidney transplantation in patients with hereditary nephropathies.

Authors:  Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

2.  Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient.

Authors:  Micah R Chan; Christie P Thomas; Jose R Torrealba; Arjang Djamali; Luis A Fernandez; Carla J Nishimura; Richard J H Smith; Millie D Samaniego
Journal:  Am J Kidney Dis       Date:  2008-09-21       Impact factor: 8.860

3.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

4.  Hemolytic uremic syndrome after renal transplantation.

Authors:  G V Vergoulas
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

Review 5.  Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Nephrol       Date:  2013-08-06

6.  KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.

Authors:  Krista L Lentine; Bertram L Kasiske; Andrew S Levey; Patricia L Adams; Josefina Alberú; Mohamed A Bakr; Lorenzo Gallon; Catherine A Garvey; Sandeep Guleria; Philip Kam-Tao Li; Dorry L Segev; Sandra J Taler; Kazunari Tanabe; Linda Wright; Martin G Zeier; Michael Cheung; Amit X Garg
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

Review 7.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 8.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 9.  The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.

Authors:  Chantal Loirat; Patrick Niaudet
Journal:  Pediatr Nephrol       Date:  2003-09-17       Impact factor: 3.714

Review 10.  Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.

Authors:  M C Pickering; H T Cook
Journal:  Clin Exp Immunol       Date:  2008-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.